Chapter 13. Use of Lipid Lowering Agents in the Prevention of Cardiovascular Disease

  1. Salim Yusuf1,
  2. John A Cairns2,
  3. A John Camm3,
  4. Ernest L Fallen4 and
  5. Bernard J Gersh5
  1. Jeffrey L Probstfield

Published Online: 4 OCT 2007

DOI: 10.1002/9780470986882.ch13

Evidence-based Cardiology, Second Edition

Evidence-based Cardiology, Second Edition

How to Cite

Probstfield, J. L. (2002) Use of Lipid Lowering Agents in the Prevention of Cardiovascular Disease, in Evidence-based Cardiology, Second Edition (eds S. Yusuf, J. A. Cairns, A. J. Camm, E. L. Fallen and B. J. Gersh), BMJ Books, London, UK. doi: 10.1002/9780470986882.ch13

Editor Information

  1. 1

    Heart and Stroke Foundation of Ontario Research Chair, Senior Scientist of the Canadian Institute of Health Research, Director of Cardiology and Professor of Medicine, McMaster, University, Hamilton Health Sciences, Hamilton, Canada

  2. 2

    Dean, Faculty of Medicine, University of British Columbia, Vancouver, Canada

  3. 3

    Professor of Clinical Cardiology and Chief, Department of Cardiological Sciences, St George's Hospital Medical School, London, UK

  4. 4

    Professor Emeritus, McMaster University, Faculty of Health Sciences, Hamilton, Canada

  5. 5

    Consultant in Cardiovascular Diseases and Internal Medicine, Mayo Clinic; Professor of Medicine, Mayo Medical School, Rochester, Minnesota, USA

Publication History

  1. Published Online: 4 OCT 2007
  2. Published Print: 20 NOV 2002

ISBN Information

Print ISBN: 9780727916990

Online ISBN: 9780470986882

SEARCH

Keywords:

  • lipid lowering agents;
  • cardiovascular disease;
  • individual lipid-altering agents;
  • HMG-CoA reductase inhibitors (statins);
  • nicotinic acid

Summary

This chapter contains sections titled:

  • Introduction

  • Use of individual lipid-altering agents

  • Informed decisions about “gray zones”

  • Costs and cost effectiveness of lipid alterations for CHD prevention

  • Summary